Juan Carlos
Montero González
Researcher from 2021
Hospital Universitario de Salamanca
Salamanca, EspañaPublications in collaboration with researchers from Hospital Universitario de Salamanca (15)
2024
-
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
International Journal of Molecular Sciences, Vol. 25, Núm. 4
-
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
Cancer Medicine, Vol. 13, Núm. 17
2023
-
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer
Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200
-
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival
International Journal of Molecular Sciences, Vol. 24, Núm. 9
2022
-
Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups
Cancers, Vol. 14, Núm. 17
-
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
2021
-
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Oncogene, Vol. 33, Núm. 2, pp. 148-156
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2009
-
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target
PLoS ONE, Vol. 4, Núm. 5
-
Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
Blood, Vol. 113, Núm. 16, pp. 3781-3791
2008
-
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225
-
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
Haematologica, Vol. 93, Núm. 1, pp. 57-66
-
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells
British Journal of Haematology, Vol. 141, Núm. 4, pp. 470-482